PMID- 16182445
OWN - NLM
STAT- MEDLINE
DCOM- 20060223
LR  - 20131121
IS  - 0304-3940 (Print)
IS  - 0304-3940 (Linking)
VI  - 392
IP  - 1-2
DP  - 2006 Jan 9
TI  - Anti-emetic activity of ghrelin in ferrets exposed to the cytotoxic anti-cancer 
      agent cisplatin.
PG  - 79-83
AB  - Emesis may be modulated via multiple mechanisms. The actions of ghrelin suggest 
      an ability to couple an induction of hunger with preparation of the stomach for 
      ingestion of food. Such a process might reduce any tendency to vomit, so an 
      anti-emetic activity of ghrelin was investigated in the ferret cisplatin-induced 
      emesis model. In controls, intra-peritoneal cisplatin (10 mg/kg) induced 
      41.4+/-8.4 episodes of emesis comprising 310.4+/-55.3 retches and 28.8+/-6.9 
      vomits during the 6h observation; the latency to onset of the first emetic 
      episode was 108.9+/-4.8 min. Intra-peritoneal ghrelin (1mg/kg, split as a 30 min 
      pre- and 30 min-post dose) did not induce a change in behaviour or modify 
      cisplatin-induced emesis (p>0.05). Intracerebroventricular (i.c.v.) 
      administration (third ventricle) was achieved via a pre-implanted cannula. At the 
      first emetic episode following cisplatin, ghrelin or vehicle (20 microl saline) 
      was administered i.c.v. During the 30 min following the initial episode of 
      emesis, control animals exhibited 18.0+/-2.6 emetic episodes comprising 
      160.3+/-24.1 retches and 13.8+/-2.7 vomits. Ghrelin 10 microg i.c.v. reduced the 
      number of retches by 61.5% (p<0.05) and at a dose of 30 microg i.c.v. ghrelin 
      reduced the number of episodes, individual retches and vomits by 74.4 (p<0.05), 
      80.4 (p<0.01), and 72.5% (p<0.05), respectively. At subsequent time periods there 
      were no differences between ghrelin- or saline-treated animals (p>0.05). An 
      ability of ghrelin to reduce emesis is consistent with a role in modulating 
      gastro-intestinal functions and identifies a novel approach to the treatment of 
      emesis.
FAU - Rudd, John A
AU  - Rudd JA
AD  - Department of Pharmacology, Faculty of Medicine, The Chinese University of Hong 
      Kong, Shatin, New Territories, Hong Kong SAR, China. jar@cuhk.edu.hk
FAU - Ngan, Man P
AU  - Ngan MP
FAU - Wai, Man K
AU  - Wai MK
FAU - King, Andrew G
AU  - King AG
FAU - Witherington, Jason
AU  - Witherington J
FAU - Andrews, Paul L R
AU  - Andrews PL
FAU - Sanger, Gareth J
AU  - Sanger GJ
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20050922
PL  - Ireland
TA  - Neurosci Lett
JT  - Neuroscience letters
JID - 7600130
RN  - 0 (Antiemetics)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Ghrelin)
RN  - 0 (Peptide Hormones)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Animals
MH  - Antiemetics/*therapeutic use
MH  - Antineoplastic Agents/*adverse effects
MH  - Behavior, Animal/drug effects
MH  - Cisplatin/*adverse effects
MH  - Disease Models, Animal
MH  - Dose-Response Relationship, Drug
MH  - Drug Interactions
MH  - Ferrets
MH  - Ghrelin
MH  - Male
MH  - Peptide Hormones/*therapeutic use
MH  - Reaction Time/drug effects
MH  - Statistics, Nonparametric
MH  - Time Factors
MH  - Vomiting/chemically induced/*prevention & control
EDAT- 2005/09/27 09:00
MHDA- 2006/02/24 09:00
CRDT- 2005/09/27 09:00
PHST- 2005/07/15 00:00 [received]
PHST- 2005/08/19 00:00 [revised]
PHST- 2005/08/31 00:00 [accepted]
PHST- 2005/09/27 09:00 [pubmed]
PHST- 2006/02/24 09:00 [medline]
PHST- 2005/09/27 09:00 [entrez]
AID - S0304-3940(05)01037-2 [pii]
AID - 10.1016/j.neulet.2005.08.062 [doi]
PST - ppublish
SO  - Neurosci Lett. 2006 Jan 9;392(1-2):79-83. doi: 10.1016/j.neulet.2005.08.062. Epub 
      2005 Sep 22.